Brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to post earnings per share (EPS) of ($1.09) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is ($1.17) and the highest is ($0.96). Crispr Therapeutics reported earnings per share of ($0.93) during the same quarter last year, which indicates a negative year over year growth rate of 17.2%. The firm is scheduled to announce its next earnings results on Monday, May 4th.

On average, analysts expect that Crispr Therapeutics will report full-year earnings of ($4.54) per share for the current fiscal year, with EPS estimates ranging from ($5.22) to ($3.70). For the next fiscal year, analysts anticipate that the firm will post earnings of ($5.05) per share, with EPS estimates ranging from ($7.14) to ($3.78). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $1.19. The business had revenue of $77.00 million during the quarter, compared to analysts’ expectations of $39.08 million. Crispr Therapeutics had a net margin of 23.09% and a return on equity of 11.74%. The firm’s revenue for the quarter was up 76900.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.92) EPS.

Several research firms have weighed in on CRSP. ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Chardan Capital restated a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Piper Sandler restated a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research report on Thursday, February 13th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Finally, Stifel Nicolaus began coverage on shares of Crispr Therapeutics in a research note on Wednesday, March 4th. They issued a “hold” rating and a $52.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Crispr Therapeutics has a consensus rating of “Buy” and a consensus price target of $72.25.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nikko Asset Management Americas Inc. lifted its stake in Crispr Therapeutics by 9.8% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,049,553 shares of the company’s stock valued at $185,733,000 after buying an additional 272,139 shares in the last quarter. ARK Investment Management LLC lifted its stake in Crispr Therapeutics by 6.3% in the fourth quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after buying an additional 174,495 shares in the last quarter. FMR LLC lifted its stake in Crispr Therapeutics by 71.8% in the fourth quarter. FMR LLC now owns 952,369 shares of the company’s stock valued at $58,004,000 after buying an additional 398,012 shares in the last quarter. Orbimed Advisors LLC bought a new position in Crispr Therapeutics in the third quarter valued at approximately $21,167,000. Finally, Franklin Resources Inc. lifted its stake in Crispr Therapeutics by 2.6% in the fourth quarter. Franklin Resources Inc. now owns 435,644 shares of the company’s stock valued at $26,533,000 after buying an additional 11,031 shares in the last quarter. 52.02% of the stock is currently owned by hedge funds and other institutional investors.

CRSP traded down $2.17 during midday trading on Wednesday, hitting $41.82. The company had a trading volume of 457,628 shares, compared to its average volume of 1,046,770. The company has a market capitalization of $2.68 billion, a PE ratio of 43.11 and a beta of 2.74. Crispr Therapeutics has a twelve month low of $32.30 and a twelve month high of $74.00. The firm’s 50-day simple moving average is $48.74 and its 200-day simple moving average is $52.90.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is an inverted yield curve?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link